[Comparison of three regimens, INH-SM-PAS, INH-SM-RFP and INH-PAS-RFP, in the original treatment cases of pulmonary tuberculosis. Report of the 13th series study (original treatment study)].
D000328:Adult; D000636:Aminosalicylic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D013307:Streptomycin / Q000009:adverse effects / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000636:Aminosalicylic Acids; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin